West Pharmaceutical Launches Synchrony S1 Prefillable Syringe
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 Jan 26
Source: Newsfilter
West Pharmaceutical Services' stock fell 4.38% as it hit a 20-day low amid a broader market decline.
The company launched the Synchrony S1 prefillable syringe system at Pharmapack 2026 in Paris, enhancing its drug delivery solutions. This launch is expected to improve West's competitiveness in the biopharmaceutical and vaccine markets, addressing the rising demand for combination products and the shift from hospital to home care. VP Stacey Vaughan emphasized the importance of this launch in light of changing market dynamics.
This product introduction positions West Pharmaceutical to better meet market needs and could lead to increased sales as the demand for innovative drug delivery systems grows.
Analyst Views on WST
Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is 348.70 USD with a low forecast of 285.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 235.890
Low
285.00
Averages
348.70
High
375.00
Current: 235.890
Low
285.00
Averages
348.70
High
375.00
About WST
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
